使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Hello, everyone. Thank you for joining us and welcome to Doximity's second quarter 2026 earnings conference call. (Operator Instructions)
各位好。感謝各位加入我們,歡迎參加 Doximity 2026 年第二季財報電話會議。(接線員指示)
I'll now hand the conference over to Perry Gold. Perry, please go ahead.
現在我把會議交給 Perry Gold。Perry,請開始。
Perry Gold - VP of Investor Relations
Perry Gold - VP of Investor Relations
Thank you, operator. Hello and welcome to Doximity's fiscal 2027 Second Quarter Earnings Call. With me on the call today are Jeff Tangney, Co-Founder and CEO of Doximity, and Matt Sonefeldt, CFO. A complete disclosure of our results can be found in our press release issued earlier today, as well as in our related Form 8-K, along with a copy of our prepared remarks, all available on our website at investors.doximity.com.
謝謝,接線員。各位好,歡迎參加 Doximity 2027 財政年度第二季財報電話會議。今天與我一同出席的有 Doximity 共同創辦人兼執行長 Jeff Tangney,以及財務長 Matt Sonefeldt。我們的完整業績揭露可見於今日稍早發布的新聞稿,以及相關的 Form 8-K(8-K 表格)文件,並附有我們的事先準備講稿;以上資料皆可於我們網站 investors.doximity.com 取得。
As a reminder, today's call is being recorded, and a replay will be available on our website. As part of our comments today, we will be making forward-looking statements. These statements are based on management's current views, expectations, and assumptions, and are subject to various risks and uncertainties. Actual results may differ materially, and we may disclaim any obligation to update any forward-looking statements or outlook.
提醒各位,今天的電話會議將被錄音,並會在我們網站提供重播。在今天的評論中,我們將作出前瞻性陳述。這些陳述係基於管理層目前的觀點、預期與假設,並可能受到各種風險與不確定性影響。實際結果可能出現重大差異,且我們可能不承擔更新任何前瞻性陳述或展望的義務。
Please refer to the risk factors in our annual report on Form 10-K, any subsequent Form 10-Qs, and any other reports and filings with the SEC that may be filed from time to time, including our upcoming filing on Form 10-Q. Our forward-looking statements are based on assumptions that we believe to be reasonable as of today's date, November 5, 2026. Of note, it is Doximity's policy to neither reiterate nor adjust the financial guidance provided on today's call unless it is also done through a public disclosure, such as a press release or through the filing of a Form 8-K. Today, we will discuss certain non-GAAP metrics that we believe aid in the understanding of our financial results. A historical reconciliation to comparable GAAP metrics can be found in today's earnings release.
請參閱我們的 Form 10-K(10-K 表格)年度報告中的風險因素、其後提交的任何 Form 10-Q(10-Q 表格)季報,以及不時向美國證券交易委員會(SEC)提交的其他報告與申報文件,包括我們即將提交的 Form 10-Q。本公司的前瞻性陳述係基於我們截至今日(2026 年 11 月 5 日)認為合理的假設。另外值得注意的是,Doximity 的政策為:除非同時透過公開揭露(例如新聞稿或提交 Form 8-K)進行,否則我們不會在今日電話會議中重申或調整所提供的財務指引。今天我們也將討論若干非 GAAP 指標,我們相信這些指標有助於理解我們的財務結果。與可比 GAAP 指標的歷史調節表可見於今日的財報新聞稿。
Finally, during the call, we may offer incremental metrics to provide greater insights into the dynamics of our business. These details may be one-time in nature, and we may or may not provide updates on those metrics in the future.
最後,在電話會議期間,我們可能會提供額外指標,以便更深入說明我們業務的動態。這些細節可能屬一次性資訊,未來我們可能會或可能不會再更新這些指標。
I would now like to turn the call over to our CEO and co-founder, Jeff Tangney. Jeff?
接下來我想把電話會議交給我們的執行長兼共同創辦人 Jeff Tangney。Jeff?
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Thanks, Perry, and thanks, everyone, for joining our Second Quarter Earnings Call. Today, I will cover three things: our financials, AI accuracy, and engagement. First, our financials. Revenue was $175 million in Q2, up 4% year-on-year and 2% above the high end of our guidance. Even with over 6x growth year-on-year in our AI spend, our Q2 adjusted EBITDA margin was 51%, or $89 million, and 9% above the high end of our guidance.
謝謝你,Perry,也謝謝各位參加我們的第二季財報電話會議。今天我將涵蓋三個主題:我們的財務表現、AI 準確性,以及使用者參與度。首先是財務表現。第二季營收為 1.75 億美元,年增 4%,並較我們指引區間上緣高出 2%。即使我們在 AI 支出方面年增超過 6 倍,第二季調整後 EBITDA 利潤率仍為 51%,即 8,900 萬美元,並較我們指引區間上緣高出 9%。
While this remains our AI investment year, we continue to have strong margins. Now to AI accuracy. It is by far the number one concern doctors have about AI. AI deals in probabilities. Patient care demands precision. All of us have had the experience of hitting refresh on an AI answer and getting a different response. Thankfully, accuracy is where we continue to lead the way.
雖然今年仍是我們投資 AI 的一年,但我們依然維持強勁的利潤率。接著談 AI 準確性。這無疑是醫師對 AI 最關切的第一大問題。AI 以機率運作。病患照護則要求精準。我們都曾有過這樣的經驗:對同一個 AI 答案按下重新整理,卻得到不同的回覆。所幸在準確性方面,我們仍持續領先。
For starters, we launched DoseCheck, a deterministic verifier for medication safety. In a study of over a quarter million AI drug dose queries across all major models, we found a 2.3% error rate. What is more, 40% of these errors are serious or even lethal. From a million AI drug queries, 9,000 patients could get hurt. That is too many. Our DoseCheck catches these errors using our built-in drug dataset.
首先,我們推出了 DoseCheck,一個用於藥物安全的確定性(deterministic)驗證器。在一項涵蓋所有主要模型、超過 25 萬筆 AI 藥物劑量查詢的研究中,我們發現錯誤率為 2.3%。更重要的是,其中 40% 的錯誤屬嚴重甚至致命。若以 100 萬筆 AI 藥物查詢計算,可能有 9,000 名病患會受到傷害。這個數字太高了。我們的 DoseCheck 會利用內建的藥物資料集來攔截這些錯誤。
It is painstaking work, and we are proud to do it. Second, we are excited to add UpToDate to our AI answers. Every clinical AI model has read the National Library of Medicine, which has all of the journals and guidelines, but Wolters Kluwer's UpToDate stands alone as the proprietary gold standard reference for point of care. Their 7,600 physician authors provide unique advice about what to do when there is not an RCT, or randomized controlled trial, to answer the question.
這是一項極其繁瑣的工作,而我們以能夠投入其中為榮。第二,我們很高興將 UpToDate 納入我們的 AI 回答中。每個臨床 AI 模型都讀過美國國家醫學圖書館(National Library of Medicine)的資料,其中包含所有期刊與指引;但 Wolters Kluwer 的 UpToDate 作為照護現場(point of care)的專有黃金標準參考資料,獨樹一幟。其 7,600 位醫師作者在缺乏 RCT(randomized controlled trial,隨機對照試驗)可回答問題時,能提供獨到的建議,說明應如何處置。
We think this real-world medical layer is really important, and now it is one tap away inside of Doximity. Independent tests keep confirming our lead in accuracy and safety. In September, we joined other vertical AI leaders like Harvey in law and Sierra in customer service to create industry-specific benchmarks. When AI provider Fireworks graded the results, Doximity ranked first among 16 leading models, echoing our Stanford NOHARM study results in July.
我們認為這層貼近真實世界的醫療知識非常重要,而現在在 Doximity 內只需輕點一下即可取得。獨立測試持續證實我們在準確性與安全性方面的領先地位。9 月,我們與其他垂直領域 AI 領導者(例如法律領域的 Harvey 與客服領域的 Sierra)共同建立產業特定的基準測試。當 AI 供應商 Fireworks 對結果進行評分時,Doximity 在 16 個領先模型中名列第一,呼應我們 7 月 Stanford NOHARM 研究的結果。
Physician input is critical to getting AI and medicine right. This quarter, we convened our Medical AI Summit, 150 physicians, chiefs, and chairs from our nation's best hospitals, joined by two former U.S. Surgeons General, Dr. Vivek Murthy and Dr. Regina Benjamin, to work through how we build clinical AI responsibly together. As a physicians-first company, this unique semi-annual event is our North Star and guides our roadmap. Finally, our engagement and client growth.
要把 AI 與醫療做對,醫師的投入至關重要。本季我們召開了 Medical AI Summit(醫療 AI 高峰會),邀集來自全美頂尖醫院的 150 位醫師、首席醫師與科主任,並有兩位前美國衛生署署長(U.S. Surgeons General)Vivek Murthy 醫師與 Regina Benjamin 醫師共同參與,一起研討我們如何負責任地共同打造臨床 AI。作為一家以醫師為先的公司,這個獨特的半年一次活動是我們的北極星,並指引我們的產品路線圖。最後,談談我們的參與度與客戶成長。
Quarterly active workflow prescribers, which includes our AI users, grew 34% year-on-year to record highs, accelerating from last quarter. For the first time, approximately half of all of the 1.8 million U.S. prescribers used us last quarter as part of their workflow. Our health system client footprint continued to grow as well, up over 190 on our AI suite from 165 last quarter, including 10 of the nation's top 20 hospitals. NewYork-Presbyterian now provides access to Doximity AI directly from its EHR, giving NewYork-Presbyterian, Columbia, and Weill Cornell Medicine clinicians convenient access to AI-powered tools and the latest medical research within their existing workflows. Over the past five years working with NewYork-Presbyterian, we have seen firsthand why they are consistently ranked among the nation's best hospitals, and we are excited to grow our AI toolset with them.
季度活躍工作流程開立處方者(包含我們的 AI 使用者)年增 34%,創下新高,且較上季加速成長。這是首次,在 180 萬名美國處方開立者中,約有一半在上季將我們作為其工作流程的一部分使用。我們的醫療體系客戶版圖也持續擴大,採用我們 AI 套件的客戶數由上季的 165 家增至超過 190 家,其中包含全美前 20 大醫院中的 10 家。NewYork-Presbyterian 現在可直接從其 EHR(電子病歷系統)存取 Doximity AI,讓 NewYork-Presbyterian、Columbia 與 Weill Cornell Medicine 的臨床人員能在既有工作流程中,便利地使用 AI 驅動工具與最新醫學研究。在過去五年與 NewYork-Presbyterian 合作的過程中,我們親眼見證他們為何能長期名列全美最佳醫院之列;我們也很期待與他們一同擴展我們的 AI 工具組。
UCSD Health, the number one ranked hospital in San Diego, is another AI client and one of the first hospitals to adopt our new Patient Context feature. Directly from a patient's chart, our AI can read that patient's notes, labs, imaging, conditions, and coverage to give patient-specific answers and guideline-based treatment plans. It's the difference between a doctor asking a general medical question and asking about the patient in front of them.
UCSD Health(加州大學聖地牙哥分校醫療體系)是聖地牙哥排名第一的醫院,也是我們的另一家 AI 客戶,並且是最早採用我們全新 Patient Context(病患情境)功能的醫院之一。我們的 AI 可直接從病患病歷中讀取該病患的病程紀錄、檢驗數據、影像、病況與保險給付資訊,提供針對病患個別情況的答案,以及依循臨床指引的治療計畫。這就是醫師提出一般醫學問題,與針對眼前這位病患提問之間的差別。
Our Patient Context feature is now available for thousands of doctors, and they're writing prompts half as long, 12 words versus our 24-word average, because they no longer have to retype the chart details into a search bar. Our AI already has the labs, notes, and problem list, so it can find the pertinent clinical details deep in their record. To fit more workflows, we're opening API access to our clinical intelligence layer.
我們的「病患情境(Patient Context)」功能現已提供給數千名醫師使用;由於他們不再需要把病歷細節重新輸入到搜尋列中,他們撰寫的提示詞長度縮短了一半,平均 12 個字,相較於我們 24 個字的平均值。我們的 AI 已經掌握檢驗數據、病歷筆記與問題清單,因此能在其病歷中深處找出相關的臨床細節。為了適配更多工作流程,我們正開放臨床智慧層的 API 存取。
If you're building time-saving tools for clinicians, we'd love to work with you. Just email us at bd@doximity.com. Last, on the pharma side, our AI Search commercial offering has been well received. 16 of the top 20 pharma companies have already purchased, with three more in contracting. More than 100 clients attended our pharma AI showcase last month, our biggest turnout ever.
如果你正在為臨床人員打造節省時間的工具,我們很樂意與你合作。請直接寄信至 bd@doximity.com。最後,在製藥端,我們的 AI Search 商業化產品反應良好。前 20 大藥廠中已有 16 家完成採購,另有 3 家正在簽約中。上個月有超過 100 位客戶參加我們的製藥 AI 展示會,創下史上最高出席人數。
To sum up, with DoseCheck and UpToDate, we lead on AI accuracy and trust. With 190 health system AI clients and Patient Context, we lead on distribution and integration. With AI Search now available to our pharma clients, we're growing into a much larger market. As always, I'd like to end by thanking my Doximity teammates who continue to work incredibly hard to care for those who care for us.
總結來說,憑藉 DoseCheck 與 UpToDate,我們在 AI 的準確性與可信度方面領先。憑藉 190 家醫療體系 AI 客戶與 Patient Context,我們在分發與整合方面領先。隨著 AI Search 現已提供給我們的製藥客戶,我們正成長進入一個更大的市場。一如既往,我想以感謝 Doximity 的團隊夥伴作結,他們持續非常努力地工作,照顧那些照顧我們的人。
With that, I'll hand it over to our CFO, Matt Sonefeldt, to walk us through our financials and guidance. Matt?
接下來,我把時間交給我們的財務長 Matt Sonefeldt,帶大家回顧財務表現與展望指引。Matt?
Matthew Sonefeldt - Chief Financial Officer
Matthew Sonefeldt - Chief Financial Officer
Thanks, Jeff. Q2 was another strong quarter for Doximity, with AI usage driving accelerated adoption of our broader workflow suite. This validates our decision to expand AI investment in FY 2027. We also improved AI cost efficiency during the quarter, which helped drive higher-than-expected profitability. Turning to our top line, Q2 revenue of $174.5 million outperformed our guidance with 4% year-over-year growth. This growth comes against a difficult year-over-year comparison versus Q2 2026, when we benefited from rapid adoption of our multi-model integrated offering.
謝謝,Jeff。第二季對 Doximity 而言又是一個強勁的季度,AI 使用量帶動我們更廣泛工作流程套件的加速採用。這也驗證了我們在 2027 財年擴大 AI 投資的決策。本季我們也提升了 AI 成本效率,進而推動獲利能力高於預期。回到營收面,第二季營收為 1.745 億美元,優於我們的指引,年增 4%。在與 2026 年第二季的艱難年對年比較下仍能成長;當時我們受惠於多模型整合式產品的快速採用。
Revenue upside in Q2 was driven by solid performance across our product portfolio, as well as growing interest in our AI Search product. Positive AI Search demand signals include pharma company customers purchasing on average more than two programs each, and the doubling of available conditions driven by customer interest.
第二季營收優於預期,主要來自我們產品組合的穩健表現,以及市場對 AI Search 產品日益升溫的興趣。AI Search 的正向需求訊號包括:製藥公司客戶平均每家購買超過兩個方案,以及在客戶需求帶動下,可用的疾病條件數量翻倍。
We believe customer engagement with AI Search continues to drive broader momentum across our entire pharma portfolio. In terms of customer metrics, our top 20 hospital and pharma customers produced net revenue retention, or NRR, of 106%, with overall NRR at 103%. Customers with greater than $500,000 in annual spend represented 82% of revenue and grew 3% year-over-year to 124%. As a reminder, these are trailing 12-month metrics.
我們認為,客戶對 AI Search 的參與度持續推動我們整體製藥產品組合的更廣泛動能。就客戶指標而言,我們前 20 大醫院與藥廠客戶的淨營收留存率(NRR)為 106%,整體 NRR 為 103%。年支出超過 50 萬美元的客戶貢獻了 82% 的營收,客戶數年增 3% 至 124 家。提醒一下,以上皆為過去 12 個月(TTM)的指標。
Turning to profitability, adjusted EBITDA in Q2 2027 was $89 million and represented a 51% margin. Outperformance was split evenly between the flow-through of higher-than-expected revenue and better-than-anticipated AI efficiency. Non-GAAP gross margin was 88% versus 92% last quarter. As we shared last quarter, the majority of the increase in cost of revenue reflects scaling our AI investment to support rapidly growing engagement. As a reminder, over 90% of our incremental AI cost is for clinician usage.
接著看獲利表現,2027 財年第二季調整後 EBITDA 為 8,900 萬美元,對應 51% 的利潤率。優於預期的部分,一半來自高於預期營收的流入效應,另一半來自優於預期的 AI 效率。非 GAAP 毛利率為 88%,相較上季的 92% 下滑。如同我們上季所分享,營收成本上升的主要原因,是我們擴大 AI 投資以支援快速成長的使用參與。提醒一下,我們新增的 AI 成本中,超過 90% 來自臨床醫師端的使用。
Even with significant engagement increases, we realized AI cost leverage. Efficiency drivers include pre-buying more capacity at favorable economics, greater multi-model usage, and continued performance gains in our proprietary harness. We are encouraged by improving AI unit economics, even as we increase the accuracy and value we deliver to clinicians.
即便參與度大幅提升,我們仍實現了 AI 成本槓桿。效率提升的驅動因素包括:以更有利的經濟條件預先購買更多算力容量、更多多模型使用,以及我們自有 harness 持續帶來的效能提升。即使我們持續提高提供給臨床醫師的準確性與價值,我們仍對 AI 單位經濟效益的改善感到鼓舞。
On a GAAP basis, stock-based compensation, or SBC, was $41 million in the quarter, or 23% of revenue. This is consistent with the low 20% SBC guidance provided last quarter. As a reminder, this year's SBC increase is primarily related to the FY 2026 grant made to our AI-focused R&D team. Excluding the grant, SBC would have been approximately 19% of revenue in Q2. We expect the impact of the AI grant to ease in FY 2028.
以 GAAP 口徑計算,本季以股份為基礎的薪酬(SBC)為 4,100 萬美元,約占營收 23%。這與我們上季提供的「SBC 約落在 20% 出頭」的指引一致。提醒一下,今年 SBC 的增加主要與我們在 2026 財年對 AI 導向研發團隊發放的授予(grant)有關。若排除該授予,第二季 SBC 約為營收的 19%。我們預期 AI 授予的影響將在 2028 財年趨緩。
Our GAAP effective tax rate was approximately 31% in the second quarter compared to 15% in the prior year, driven by the tax treatment of equity compensation. Our non-GAAP effective tax rate remained at 21%. In Q2, GAAP diluted EPS was $0.18 per share, and non-GAAP diluted EPS was $0.36 per share. Fully diluted shares declined by 13 million, down 6% year-over-year to 188 million shares outstanding.
第二季我們的 GAAP 有效稅率約為 31%,相較前一年為 15%,主要受股權薪酬稅務處理方式影響。我們的非 GAAP 有效稅率維持在 21%。第二季 GAAP 稀釋後每股盈餘(EPS)為每股 0.18 美元,非 GAAP 稀釋後 EPS 為每股 0.36 美元。完全稀釋股數減少 1,300 萬股,年減 6%,期末流通在外股數為 1.88 億股。
Our balance sheet and cash flow generation remain strong. We ended Q2 2027 with $713 million in cash equivalents, and marketable securities, and we remain debt-free. We generated $91 million of free cash flow, outpacing adjusted EBITDA and up from $40 million in Q1. As expected from last quarter, collections activity normalized. During the quarter, we repurchased $54 million of shares. We believe share repurchases remain an attractive, opportunistic use of capital.
我們的資產負債表與現金流創造能力依然強勁。2027 財年第二季期末,我們持有 7.13 億美元的現金約當物與有價證券,且維持零負債。我們產生 9,100 萬美元的自由現金流,超過調整後 EBITDA,並較第一季的 4,000 萬美元增加。正如上季所預期,收款活動已回歸常態。本季我們回購了 5,400 萬美元的股票。我們認為股票回購仍是具吸引力、可伺機而為的資本運用方式。
As of September 30th, we had approximately $347 million remaining in our existing repurchase program. Let's turn to our outlook. For revenue in Q3, we expect a range of $195 million-$196 million, representing 6% year-over-year growth at the midpoint. For FY 2027, we have raised our revenue guidance range to $678 million-$683 million, also representing 6% growth at the midpoint. We expect slight acceleration in second-half revenue growth versus first half on a year-over-year basis.
截至 9 月 30 日,我們在既有回購計畫中仍約有 3.47 億美元的剩餘額度。接著談展望。第三季營收方面,我們預期區間為 1.95 億至 1.96 億美元,以中位數計算年增 6%。就 2027 財年而言,我們將營收指引區間上調至 6.78 億至 6.83 億美元,以中位數計算同樣年增 6%。我們預期下半年營收年對年成長將較上半年略為加速。
For FY 2027, we are increasing the guidance midpoint by $4.5 million. This reflects the flow-through of our Q2 outperformance, plus a modest incremental raise driven by growing visibility into the commercial AI pipeline. AI Search is now an eight-figure bookings product, and we started recognizing revenue from the product when the first program launched in July. As a reminder, Q3 is our upfront season.
針對 2027 財年,我們將指引中位數上調 450 萬美元。這反映第二季優於預期表現的流入效應,並加上因商業化 AI 管線能見度提升所帶來的小幅額外上調。AI Search 現已成為一項「八位數」訂單額(bookings)產品,我們也在 7 月首個方案上線時開始認列該產品的營收。提醒一下,第三季是我們的 upfront 旺季。
This is when most pharma clients commit the majority of their marketing budgets for next year's programs in what are called upfront contracts. It is the largest booking quarter of the year, and most contracts are signed by the end of December. We then typically recognize those commitments as revenue over the following 12 months, depending on the timing of program launches.
這段期間,多數製藥客戶會透過所謂的 upfront 合約,承諾其明年方案的大部分行銷預算。這是全年最大的訂單(booking)季度,多數合約會在 12 月底前完成簽署。之後我們通常會依據方案上線時點,在接下來 12 個月內將這些承諾認列為營收。
One key difference this year is the availability of our new AI Search product. To date, we've seen early broad-based adoption with 16 of the top 20 pharma companies having purchased programs, and three more are in our pipeline. We will provide an update about the upfront and AI Search progress in our February call. In Q4, we expect year-over-year revenue growth to be similar to the Q3 guided growth rate. As with prior years, we have lower visibility into Q4 until we finish the upfront.
今年的一項關鍵差異在於我們全新 AI Search 產品的可用性。截至目前,我們已看到早期且廣泛的採用:前 20 大製藥公司中已有 16 家購買了方案,另有 3 家正在我們的銷售管線中。我們將在 2 月的電話會議中,就 upfront(預售)與 AI Search 的進展提供更新。在第四季,我們預期年對年營收成長將與第三季指引的成長率相近。與往年相同,在完成 upfront 之前,我們對第四季的能見度較低。
In addition, new products like AI Search have a steeper ramp in the first calendar quarter of a new year, as we help new customers through the medical-legal review process. As a result, we expect a gradual ramp in AI Search revenue throughout calendar 2027. For adjusted EBITDA, in Q3, we expect a range of $102.5 million-$103.5 million, representing a 53% adjusted EBITDA margin at the midpoint.
此外,像 AI Search 這類新產品在新年度的第一個曆年季度通常有較陡峭的爬坡期,因為我們會協助新客戶完成醫療—法務審查流程。因此,我們預期 AI Search 的營收將在 2027 曆年期間逐步爬坡。就調整後 EBITDA 而言,第三季我們預期區間為 1.025 億至 1.035 億美元,以中位數計算相當於 53% 的調整後 EBITDA 利潤率。
For FY 2027, we now expect a revised range of $317 million-$325 million, representing a 47% adjusted EBITDA margin at the midpoint. This outlook incorporates the continued investment required to support the stronger-than-expected AI engagement we've seen this year. In the second half of FY 2027, we'll continue to invest in growing clinician AI usage and expanding our moats.
對於 2027 財年,我們目前預期修正後區間為 3.17 億至 3.25 億美元,以中位數計算相當於 47% 的調整後 EBITDA 利潤率。此展望納入了為支援今年我們所見到、強於預期的 AI 互動所需的持續投資。在 2027 財年下半年,我們將持續投資以提升臨床醫師的 AI 使用量並擴大我們的護城河。
Key initiatives include increased safety and accuracy through programs like DoseCheck, greater clinical content through partners like UpToDate, and growing distribution leadership with US health systems. In closing, our long-term approach remains unchanged. We will continue to deliver one platform for AI clinical decision support, documentation, and patient communication. Improving efficiency in our AI investments allows us to continue playing offense in the midst of this generational technology shift and help our clinicians be more productive so they can provide better care for their patients. Lastly, as a reminder, you can find our modeling considerations appendix in our prepared remarks, where you can see more detailed financial commentary.
關鍵舉措包括:透過 DoseCheck 等方案提升安全性與準確性;透過 UpToDate 等合作夥伴擴充臨床內容;以及與美國醫療體系合作,強化我們在通路上的領導地位。最後總結,我們的長期策略維持不變。我們將持續提供單一平台,用於 AI 臨床決策支援、文件記錄與病患溝通。提升 AI 投資效率,使我們能在這場世代性的技術轉變中持續主動出擊,並協助臨床醫師提升生產力,從而為病患提供更好的照護。最後提醒,您可在我們的預先準備講稿中找到「建模考量」附錄,其中包含更詳細的財務評論。
With that, I will turn it over to the operator for questions.
接下來,我把時間交給接線員進行提問。
Operator
Operator
(Operator Instructions)
(接線員指示)
Brian Peterson, Raymond James.
Brian Peterson,Raymond James。
Brian Peterson - Equity Analyst
Brian Peterson - Equity Analyst
Hi, gentlemen. Thanks for taking the question. Jeff, I was encouraged by your comments on AI Search, the eight-figure bookings, 16 of the top 20 with more on the way. Maybe you could talk about how that kind of built over the course of this year versus your expectations, and is there anything qualitative that you could share about what that could do for your positioning into 2027?
嗨,各位先生。謝謝讓我提問。Jeff,你對 AI Search 的評論讓我很受鼓舞:八位數的訂單額、前 20 大中已有 16 家採用,且還有更多正在進來。也許你可以談談這一年來這些成果是如何逐步建立、相較於你原先的預期如何;以及是否能分享一些質性的觀察,說明這對你們在邁向 2027 年的市場定位可能帶來什麼影響?
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Yeah, thanks, Brian. This is Jeff. I'll say qualitatively, search is exciting to our clients and to us. We've had more what they call top-to-top meetings with pharma companies, chief marketing officers, CEOs in the top 20, and they're going really well. It's an exciting time. We're getting real insight into the real problems that real patients and real doctors have without having to fly around and do lots of focus groups and rep rides and things that, frankly, aren't as efficient. We're excited about that. We think we're entering a whole new market here, which has historically been paid search. I'll give a hat tip to Bank of America. They did a survey of 35 pharma marketers, completely independent survey. We had nothing to do with it.
好的,謝謝你,Brian。我是 Jeff。我先從質性角度說,搜尋對我們的客戶以及對我們而言都很令人振奮。我們與製藥公司進行了更多所謂的「高層對高層」會議,包含前 20 大公司的行銷長、執行長等,而且進展非常順利。這是一個令人興奮的時刻。我們正在獲得對真實病患與真實醫師所面臨真實問題的洞察,而不必到處飛、做大量焦點團體、跟診拜訪等;坦白說,那些方式效率沒那麼高。我們對此感到很興奮。我們認為我們正在進入一個全新的市場,而這個市場過去主要是付費搜尋。我也要向美國銀行致意。他們對 35 位製藥行銷人員做了一份調查,完全獨立的調查。我們完全沒有參與。
They asked, If you had more incremental budget, more to spend on marketing, who would you spend more with? We hit an all-time high with 81% of the respondents saying they'd spend more with us, and I think that's because of the traction we're seeing with our 190 health system partners and AI Search growth. Interestingly, the group that fell the most there was paid search or Google, which fell to only 6% of the respondents saying that they would spend incrementally there. I think that's proof that with AI Search, we are entering search budgets, which is about $14 billion a year in the United States, according to EMARKETER, just for pharma. So, $14 billion a year spent on paid search. That is a much larger market than we have been in historically, and we're excited to enter it.
他們問:如果你有更多增量預算、可以在行銷上多花一些,你會把更多預算花在誰身上?我們達到歷史新高,有 81% 的受訪者表示會在我們這裡增加支出;我認為這是因為我們與 190 家醫療體系合作夥伴的進展,以及 AI Search 的成長動能。有趣的是,下滑最多的類別是付費搜尋或 Google,只有 6% 的受訪者表示會把增量預算花在那裡。我認為這證明了透過 AI Search,我們正在切入搜尋預算;根據 EMARKETER 的資料,僅就美國製藥產業而言,這大約是每年 140 億美元。也就是每年 140 億美元花在付費搜尋上。這是一個比我們過去所處市場大得多的市場,我們很興奮能夠進入。
As I think of the build over the course of this year, I think we will continue to see a big upfront there. But starting early next year or late this year with a couple pilot clients, we will also offer a biddable or auction-based purchasing there, which does make things a lot easier for our clients and for us. Again, brings us into an exciting whole new world that is more like paid search and less like endemic marketing.
回顧今年一路走來的建立過程,我認為我們在 upfront 方面仍會看到很大的規模。但從明年初或今年稍晚開始,搭配幾個試點客戶,我們也會提供可競價或拍賣式的購買方式,這會讓客戶與我們的操作都容易許多。同樣地,這也把我們帶進一個令人興奮的全新世界,更像付費搜尋、而較不像傳統的垂直領域行銷。
Brian Peterson - Equity Analyst
Brian Peterson - Equity Analyst
Appreciate the color. Maybe just a follow-up. I wanted to hit on some of the AI compute things that you mentioned in terms of efficiency measures.
謝謝補充說明。我再追問一下。我想談談你提到的一些 AI 算力相關事項,尤其是效率措施方面。
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Sure.
當然。
Brian Peterson - Equity Analyst
Brian Peterson - Equity Analyst
In terms of multimodal usage or some of the performance gains from your harness, could you guys unpack that a bit? I know that has been a key topic of conversation with investors. Thanks, guys.
就多模態使用,或你們的 harness 帶來的一些效能提升而言,你們能否再拆解說明一下?我知道這一直是投資人討論的重點話題。謝謝各位。
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Sure. Matt can speak to this a bit as well. I just spoke at the Fireworks Conference a couple days ago. There is a lot going on in AI inference right now, and most of it is good for companies like us in that there are just more options and the platforms are getting more flexible to be able to handle, again, the security and medical needs that we have. We have a great team here. I will say I continue to be very pleased with the Pathway acquisition and the new hires. We have kept almost all of our AI team, so no turnover. From our end, we are really excited about, again, all the new software tools that are allowing us to do our jobs better and helping doctors make better decisions at the point of care.
當然。Matt 也可以補充一些。我幾天前剛在 Fireworks Conference 發表演講。目前 AI 推論領域有很多進展,而其中大多數對我們這類公司是利多,因為可選方案更多、平台也更具彈性,能夠處理我們所需的安全性與醫療需求。我們這裡有一支很強的團隊。我想說,我對 Pathway 的收購以及新進人員的加入仍然非常滿意。我們幾乎留住了所有 AI 團隊成員,所以沒有流失。就我們而言,我們對各種新的軟體工具感到非常興奮;這些工具讓我們能把工作做得更好,也能在照護現場協助醫師做出更好的決策。
Matthew Sonefeldt - Chief Financial Officer
Matthew Sonefeldt - Chief Financial Officer
Yeah, I can just pile on a little bit. I think honestly, the most important AI investment metric we have is just accelerated engagement, right? Speaks to us kind of rapidly engaging with clinicians through Ask, through Scribe, through what is now the most accurate clinical AI product in the market. I think that's a good place for us to be. The accelerated engagement is the proof point. I think we're also getting better at learning how to develop with the infrastructure. All the things that we talked about in the prepared remarks, better performance on our proprietary harness, more multimodal deployments, buying more capacity and compute upfront, all of those things help. I think maybe my favorite financial metric from the quarter was our cost of revenue grew at less than half of our overall prompt volume in Q2.
我也再補充一點。我認為老實說,我們最重要的 AI 投資衡量指標就是互動加速,對吧?這反映我們正透過 Ask、透過 Scribe,以及透過目前市場上最準確的臨床 AI 產品,快速與臨床醫師建立互動。我認為這對我們來說是個很好的位置。互動加速就是最好的佐證。我也認為我們在學習如何用既有基礎設施進行開發方面變得更擅長。我們在預先準備講稿中提到的所有事項——我們自有 harness 的更佳效能、更多多模態部署、提前購買更多容量與算力——這些都有幫助。我想本季我最喜歡的一個財務指標是:我們第二季的營收成本增幅不到整體 prompt 量增幅的一半。
In Q1, those two things were pretty similar, right? Our cost of revenue grew at a much higher rate, at a similar rate as prompt volume. I think we've shown that we can be efficient as we deliver great results. Look forward to keeping that up.
在第一季,這兩件事其實相當接近,對吧?我們的營收成本成長速度高得多,與提示(prompt)量的成長速度相近。我想我們已經證明,在交付優異成果的同時,我們也能維持高效率。期待能持續保持這樣的表現。
Operator
Operator
Michael Cherny, Leerink Partners.
Michael Cherny,Leerink Partners。
Michael Cherny - Equity Analyst
Michael Cherny - Equity Analyst
Great. Thanks so much. Maybe just one, Jeff, here if I can. I would love to get a little bit more detail on the UpToDate partnership. First time we've heard from you since that was announced. Wolters Kluwer clearly a well-regarded partner in the market, but how did you settle on that being the right partner at this point in time as you build out your AI capabilities? As you think about what your other opportunities were, what else was the range of outcomes that landed here and landed at this being the right and the best partner at this point in time in particular? Thank you.
很好。非常感謝。Jeff,如果可以的話,我這邊也許再問一個。我想更深入了解一下與 UpToDate 的合作夥伴關係。自從那項合作宣布以來,這是我們第一次聽到你們的說法。Wolters Kluwer 顯然是在市場上備受推崇的合作夥伴,但在你們建構 AI 能力的此刻,你們是如何判定它就是此時此刻的合適夥伴?當你們思考其他可能的機會時,當時可能的結果範圍是什麼?最後是哪些因素讓你們走到這一步,並認定在此時此刻它是正確且最佳的合作夥伴?謝謝。
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Thanks, Michael. Yes, we are excited, super excited to work with UpToDate. They are picky. They are the number one player in the market, the most used, most trusted. I think Evercore ran a survey on this a little earlier this year. I mean, they are far and away, head and shoulders above anyone else. I like to joke, IQVIA-like market share when it comes to being the clinical decision support point-of-care tool for doctors. Most used, most trusted by far. Like I said, they are choosy, so they have chosen to work with Epic, Microsoft, and us, and frankly, not many others. I think what we are bringing Greg and his team is a lot of AI savvy when it comes to being able to pull in broader, faster-moving evidence segments.
謝謝你,Michael。是的,我們很興奮,超級興奮能與 UpToDate 合作。他們很挑剔。他們是市場第一名,是使用最廣、最受信任的。我記得 Evercore 今年稍早對此做過一份調查。他們的領先幅度非常大,遠遠把其他人甩在後面。我常開玩笑說,就作為醫師臨床決策支援的即時照護(point-of-care)工具而言,他們的市占率有點像 IQVIA 那樣。使用最多、信任度最高,差距非常明顯。如我所說,他們很挑,所以他們選擇與 Epic、Microsoft,以及我們合作,坦白說,其他合作對象並不多。我認為我們帶給 Greg 和他團隊的,是在 AI 方面的深厚能力,特別是在能夠納入更廣泛、變動更快的證據(evidence)片段。
What they bring us, and uniquely in the market, is keep in mind, everyone has access to all of the journals that are paid for largely by government grants and are all in the National Library of Medicine. Everyone has access to all that, all the frontier models, but very, very few none of the frontier models have access to UpToDate. So, we are excited about that. We are just getting out in market with it now. It has been just a couple weeks since our announcement, but the client reaction to it has been very positive. I would just say the partnership and the people also have been very synergistic. UpToDate is a mission-driven company, similar values to us and our team.
而他們帶給我們的、且在市場上相當獨特的是:請記住,所有人都能取得那些期刊內容——這些期刊多半由政府補助金資助,並收錄在美國國家醫學圖書館(National Library of Medicine)中。大家都能取得那些內容,也都能取得所有前沿模型(frontier models),但非常、非常少——幾乎沒有任何前沿模型能取得 UpToDate 的內容。所以我們對此非常興奮。我們現在才剛開始把它推向市場。距離我們宣布合作也才短短幾週,但客戶對此的反應非常正面。我也想說,這次合作以及雙方的人員合作起來也非常有綜效。UpToDate 是一家使命導向的公司,價值觀與我們及我們的團隊相近。
Again, it seems to be just a strong synergy of our AI evidence tools and their unique expert opinion and physician expertise in that medical layer of knowledge that frankly is not in a randomly controlled trial or published area. Final point of note, we have significant customer overlap. They have 2,500 health systems as clients. We have 190. So we see a lot of overlap between our client base, and that also creates additional synergies for us. Anyway, very excited about UpToDate, and you will see more from us with them over the coming quarters. We are just getting started.
再者,這看起來確實是我們的 AI 證據工具,與他們在醫學知識層面上獨特的專家意見與醫師專業之間的強大綜效——坦白說,那些知識並不會出現在隨機對照試驗或已發表的文獻領域中。最後補充一點,我們的客戶重疊度很高。他們有 2,500 家醫療體系客戶。我們有 190 家。因此我們看到雙方客戶基礎有大量重疊,這也為我們帶來額外的綜效。總之,我們對 UpToDate 非常興奮,接下來幾個季度你會看到我們與他們有更多進展。我們才剛起步。
Operator
Operator
Craig Hettenbach, Morgan Stanley.
Craig Hettenbach,Morgan Stanley。
Craig Hettenbach - Analyst
Craig Hettenbach - Analyst
Thank you. Jeff, on the point of around half of prescribers now using the workflow tool, could you just touch on what's driving the acceleration there, and then what type of signal may that provide for growth in the coming quarters?
謝謝。Jeff,關於目前大約有一半的開立處方者(prescribers)正在使用工作流程工具這點,你能否談談是什麼在推動這個加速,以及這可能為未來幾季的成長提供什麼樣的訊號?
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Thanks, Craig. Yeah, that's a real milestone for us as a company to have over half of all US prescribers, and there are about 1.8 million US prescribers, so about over 900,000 US prescribers, and that's MD, DO, NP, or PAs, so folks who can legally write prescriptions in the US, to have over half of them in the last quarter use our workflow tools is a big milestone. We've never been that big before, and again, as we said, that's up 34% year-on-year. It's a good question. What's the biggest drivers? The two biggest areas there are telehealth and scheduling. So telehealth continues to grow in this country. It's very popular, especially in disease categories like diabetes, and let's face it, doctors are finding it's more efficient, and patients, of course, appreciate the no commute of being able to see your doctor virtually during the day.
謝謝你,Craig。是的,對我們公司而言,這是一個真正的里程碑:全美所有開立處方者中有超過一半在使用我們的工作流程工具。美國大約有 180 萬名開立處方者,所以大約超過 90 萬名;這包含 MD、DO、NP 或 PA,也就是在美國依法可以開立處方的人。上個季度有超過一半使用我們的工作流程工具,這是很大的里程碑。我們以前從未達到這麼大的規模;而且如我們所說,這是年增 34%。這是個好問題。最大的驅動因素是什麼?兩個最大的領域是遠距醫療(telehealth)與排程(scheduling)。因此,遠距醫療在這個國家持續成長。它非常受歡迎,尤其是在像糖尿病這類疾病領域;而且坦白說,醫師發現這樣更有效率,病患當然也很喜歡不用通勤、能在白天以線上方式看診。
We're seeing a lot of doctors now have a half day or full day a week that is just dedicated to work from home telehealth, and we think that's better for doctors and their overall work-life balance and sanity. It's better for patients. We're really proud to help power it, and again, we've never done as many telehealth calls as we did this last quarter. We're again seeing continued growth there, kind of quietly. During COVID, we talked about telehealth a lot, and then it sort of receded, but we're well above the call volumes that we were doing during COVID now, and so we're just seeing continued growth here in 2023, 2024, 2025, 2026. Scheduling also is a growth area for us.
我們看到現在有很多醫師每週會有半天或一整天專門用來在家進行遠距看診;我們認為這對醫師及其整體工作與生活平衡、以及心理狀態都更好。這對病患也更好。我們非常自豪能協助提供這樣的能力;而且同樣地,我們上個季度完成的遠距看診通話量創下新高。我們也再次看到那邊持續成長,某種程度上是默默地在成長。在 COVID 期間,我們談了很多遠距醫療,之後討論熱度似乎下降,但我們現在的通話量已遠高於 COVID 期間;因此我們在 2023、2024、2025、2026 年都持續看到成長。排程對我們而言也是一個成長領域。
Doctors, of course, need to have their schedule, all their shifts, and we make it easy to call each other, secure message them, so that's a continued growth area for us. Those are the two I'd point to. The third, of course, is AI, which we've already been talking about a lot, but the reality is that's a whole new category of usage and growth for us, and I am particularly excited about the thousands of doctors we have now using the full Patient Context. So, doctors don't want to go type the full patient history into a search bar. They want a suite, not a search bar, and that's what we offer them. We offer them a suite, not a search bar.
醫師當然需要管理他們的行程、所有班表;我們讓他們彼此通話、以安全訊息互傳變得更容易,所以這也是我們持續成長的領域。以上是我會特別指出的兩點。第三個當然是 AI,我們已經談了很多;但現實是,這對我們而言是一個全新的使用與成長類別,而我特別興奮的是,現在已有數千名醫師在使用完整的 Patient Context(病患情境)。醫師不想把完整的病史打進搜尋列。他們想要的是一整套工具,而不是一個搜尋列,而這正是我們提供給他們的。我們提供的是一整套工具,而不是一個搜尋列。
That suite allows them to do the telehealth visit, to have notes taken on that visit, what we call Scribe, and then to ask questions about that visit with the Patient Context. Again, that's the most efficient way to get the best care in this country, and we're seeing that with that full Patient Context, there are already cases of tough diagnoses that probably would have taken a lot longer, right? Specialist visits and lots of follow-ups, and AI is really very good at finding that rare fascinoma on page 89 and triangulating that into a patient that has a one in 100,000 disease. I don't know, it's just so fulfilling for me that my eyes get wide, and frankly, it's right to the core of our mission to help doctors, again, provide better care.
那套工具讓他們能進行遠距看診、在看診過程中完成筆記記錄(我們稱之為 Scribe),然後再透過 Patient Context 針對這次看診提出問題。同樣地,這是以最高效率提供最佳照護的方式,而我們也看到在完整 Patient Context 的協助下,已經出現一些棘手診斷案例——原本可能需要更久時間,對吧?可能需要專科門診與多次追蹤;而 AI 非常擅長在第 89 頁找到那個罕見的「fascinoma」,並把線索交叉比對到一位罹患十萬分之一罕見疾病的病患身上。我不知道,這對我來說真的很有成就感,讓我眼睛一亮;坦白說,這也正切中我們的使命核心:再次協助醫師提供更好的照護。
That Patient Context in that suite and that AI growth, which is over half of our workflow users, those are the three big growth areas: telehealth, scheduling, and AI Search.
在該套件中的 Patient Context,以及 AI 的成長(其使用者已超過我們工作流程使用者的一半),這三者是三大成長領域:遠距醫療、排程,以及 AI 搜尋。
Matthew Sonefeldt - Chief Financial Officer
Matthew Sonefeldt - Chief Financial Officer
Craig, I think you asked a little bit as well about how that leads into a monetization opportunity. I think I draw upon some of my experience in consumer web, in particular at LinkedIn, and I think in those models, and it's the same business model that we have, your engagement growth leads your monetization opportunity. I like that we're building our engagement growth the right way based on workflow, based on the value that we're adding for our clinician users, and I'd be remiss if I didn't point out that a year ago, our workflow active user growth was in the single digits. Today, it's 34%, so it's accelerated dramatically. I think that just gives us a pretty incredible opportunity over the next couple of years to grow our business as well, so we're really excited about that.
Craig,我想你也稍微問到這如何帶來變現機會。我會借鏡我在消費者網路領域的部分經驗,特別是在 LinkedIn;在那些模式中(而且這也正是我們的商業模式),互動成長會帶動你的變現機會。我喜歡我們以正確的方式來建立互動成長:以工作流程為基礎、以我們為臨床使用者所增加的價值為基礎;如果我不指出一點就太失職了——一年前,我們的工作流程活躍使用者成長還是個位數。今天是 34%,所以加速非常明顯。我認為這在未來幾年也為我們帶來相當驚人的機會去成長我們的業務,所以我們對此非常興奮。
Craig Hettenbach - Analyst
Craig Hettenbach - Analyst
That's helpful context. Thanks. Then just as a follow-up, Matt, nice to see the upside to margins in the quarter and the guide. You pointed to some things in terms of efficiencies. As you kind of play this out, is there anything else you would point to in terms of perhaps building confidence of operating leverage in the business?
這些背景資訊很有幫助。謝謝。接著追問一下,Matt,很高興看到本季以及指引的毛利率/利潤率有上行空間。你提到了一些效率面的因素。當你把這件事往後推演時,還有沒有其他你會指出的重點,來幫助建立大家對公司營運槓桿的信心?
Matthew Sonefeldt - Chief Financial Officer
Matthew Sonefeldt - Chief Financial Officer
Yeah. I think we talked a little bit about this in the last quarter earnings call, where this is a matter of time sequencing, right? In order to drive that network engagement, the value for our users, that happens before you drive the monetization that follows it. There is nothing about any of the AI investments and the early monetization we are seeing with AI Search that would suggest that our margin profile would be dramatically different. Potentially, it could even be better over time, although that is not necessarily what we are over-optimizing for. But I think more than anything else, we are really encouraged about the incremental margins that we will see in the business as we really start to scale AI Search in FY 2028 and beyond. Nothing gives us pause there, and revenue is going to be the ultimate thing that gives us the most leverage.
有。我想我們在上一季的財報電話會議中也稍微談過,這其實是時間先後順序的問題,對吧?為了推動網路互動、為使用者創造價值,這會發生在你推動後續變現之前。就我們在 AI 的投資,以及我們在 AI 搜尋上看到的早期變現而言,沒有任何跡象顯示我們的利潤率結構會出現大幅不同。隨著時間推進,甚至可能會更好,雖然這不一定是我們最優先要過度最佳化的目標。但我認為最重要的是,當我們在 2028 財年及之後真正開始擴大 AI 搜尋規模時,我們對於業務將看到的增量利潤率感到非常受鼓舞。這方面沒有任何讓我們猶豫的地方,而營收將是最終帶來最大槓桿的關鍵。
I think some of the efficiency on the cost side just gives us more encouragement in that direction from this past quarter.
我認為成本端的一些效率提升,也讓我們對這個方向更有信心,這是從上一季所看到的。
Craig Hettenbach - Analyst
Craig Hettenbach - Analyst
Got it. Thanks.
了解。謝謝。
Operator
Operator
Ryan Daniels, illiam Blair.
Ryan Daniels,William Blair。
Ryan Daniels - Analyst
Ryan Daniels - Analyst
Yeah. Thanks for all the color, and thanks for taking the question. Jeff, one for you, and you talked a little bit about this, but I want to dive a little bit deeper into it. With 16 of the top 20 pharma clients buying AI Search solutions, are you able to tell if that's at all cannibalizing any of your other sales with them, or is it really all proving to be incremental at this point?
是的。謝謝你們提供這麼多細節,也謝謝讓我提問。Jeff,有一題想請教你;你剛剛有稍微提到,但我想再深入一點。在前 20 大藥廠客戶中有 16 家購買 AI 搜尋解決方案的情況下,你們能否判斷這是否在某種程度上侵蝕了你們與他們之間的其他銷售,還是說到目前為止基本上都證明是增量?
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Yeah, it's a good question, Ryan. I'd say it's mostly incremental. Of course, it's impossible to know that exactly. But I think we will know that exactly when we offer it as a biddable solution where they're purchasing it, usually out of a separate team that is more of a search team, because it's more of a keyword-driven approach to marketing, and that typically is a separate marketing team within our client. It's mostly incremental. I can't promise you it's 100% incremental, but I will say, going back to that survey of pharma marketers that was done, we're proud to be at an all-time high, 81% incremental spend, and I think that's mostly that paid search bucket that we are now entering, $14 billion a year spent on Google by pharma per year.
是的,這是個好問題,Ryan。我會說大多是增量。當然,不可能完全精確地知道。但我認為,當我們把它作為可競價(biddable)的解決方案推出、由他們實際採購時,我們就能非常清楚地知道;通常採購會由一個獨立的團隊進行,更像是搜尋團隊,因為這是一種以關鍵字驅動的行銷方式,而在我們的客戶內部,這通常是不同的行銷團隊。所以大多是增量。我不能保證 100% 都是增量,但我會說,回到那份針對藥廠行銷人員所做的調查,我們很自豪目前達到歷史新高——81% 的增量支出;我認為那主要就是我們現在正在切入的付費搜尋(paid search)那個桶,藥廠每年在 Google 上花 140 億美元。
It is interesting in that same survey that Google is at an all-time low at 6%. Again, mostly incremental, and the excitement to be able to really be in those highly relevant contextual places is something that we're excited about.
同一份調查也很有意思:Google 的占比降到歷史新低的 6%。再次強調,主要是增量;而能夠真正出現在那些高度相關、具情境的場域中,這點讓我們非常興奮。
Matthew Sonefeldt - Chief Financial Officer
Matthew Sonefeldt - Chief Financial Officer
Ryan, the only other thing I'll add, there was some of the language in the prepared remarks that you'll see around Q2, but we saw positive growth in Q2 across all of our major product categories, and that's really encouraging. While the AI Search pipeline is continuing to grow, it's still early days and pretty nascent. Most of what we're kind of seeing in the upfront cycle so far, again, early in the cycle, is demand for our core products, whether it's in the Newsfeed or it's video around Dialer and telehealth. I think we're in a good place with a solid foundation to build AI Search on top of. So, I think that's encouraging for us too as we go throughout the year.
Ryan,我唯一想再補充的是,你會在事先準備的講稿中看到一些關於第二季的措辭;但我們在第二季於所有主要產品類別都看到正成長,這非常令人鼓舞。雖然 AI 搜尋的銷售管線仍在持續成長,但目前仍屬早期階段、相當新。到目前為止,我們在預售(upfront)週期中看到的大多數情況——同樣地,週期才剛開始——是對我們核心產品的需求,不論是 Newsfeed,或是圍繞 Dialer 與遠距醫療的影片產品。我認為我們處於一個很好的位置,擁有穩固的基礎,能在其上建構 AI 搜尋。所以,我想這也讓我們在今年接下來的推進中感到鼓舞。
Ryan Daniels - Analyst
Ryan Daniels - Analyst
Yeah. Super helpful color. And then, Jeff, as my follow-up, it seems like we are seeing a lot tighter governance among health systems, especially bigger ones or academics, about how doctors use AI. Early on, maybe just download a free tool, but now they are getting a lot more concerned about liability and patient care, and I am curious how that plays into your advantage given the outcomes you have been able to present, like you talked about earlier, plus the massive channel distribution you have with your Dialer asset into those enterprise accounts. Thanks.
是的,這些細節非常有幫助。接著,Jeff,作為追問:看起來我們看到醫療體系(尤其是大型體系或學術機構)在醫師如何使用 AI 方面的治理變得更嚴格。早期可能只是下載一個免費工具,但現在他們對責任風險與病患照護更為擔憂;我很好奇,考量到你們能提出的成果(如你先前提到的),再加上你們透過 Dialer 資產在這些企業級客戶中的龐大通路覆蓋,這如何轉化為你們的優勢。謝謝。
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Yeah. Thanks, Ryan. Yeah, I think on last quarter's call, we had made some comments about AI accountability. That is the next age or next phase for our health system clients, which we did grow from 165 to 190, so 25 new clients in the last quarter, and we are going to keep growing there. We have over 300 enterprise clients overall on our telehealth and other products, and we have privacy agreements in place with all of them, but we do not have the AI review with all of them. But that 300 enterprise clients that we have are nearly half of all U.S. physicians, so we cover all the largest health systems. Again, that is where we really see this AI growth and TAM. One specific case that came out this last week was Johns Hopkins.
是的,謝謝你,Ryan。是的,我想在上一季的電話會議上,我們曾對 AI 問責(accountability)做過一些評論。那是我們醫療體系客戶的下一個時代或下一個階段;我們的醫療體系客戶數從 165 增加到 190,也就是上一季新增 25 家客戶,而且我們會持續在這方面成長。我們在遠距醫療與其他產品上,整體有超過 300 家企業級客戶;我們與所有客戶都已簽有隱私協議,但並非與所有客戶都完成 AI 審查。但我們擁有的這 300 家企業級客戶,涵蓋了接近全美一半的醫師,因此我們覆蓋所有最大的醫療體系。再次強調,這正是我們真正看到 AI 成長與 TAM(總可服務市場)的地方。上週有一個具體案例是 Johns Hopkins。
They had 3,000 patients that they had to send an email out to, which is not fun for anyone to do, telling them that an employee had uploaded some of their data to an unapproved AI. So, when we see things like that happen, and we have seen a bunch of other health systems put in IP-level block, I think we are just going to see more of that happen because the reality is people should be concerned about the security of their patient data being put into AI that may leak out in various places. So, I think we are moving beyond the Wild West phase of AI in health systems. We are proud to announce NYP this quarter as a new AI logo. We are proud to announce UCSD, both top- 20 hospitals, as a new logo. But I do think you are right.
他們有 3,000 名病患必須寄出電子郵件通知——這對任何人來說都不是件愉快的事——告知有員工把部分資料上傳到未經核准的 AI。當我們看到這類事件發生,而且我們也看到其他許多醫療體系在 IP 層級設置封鎖,我認為這種情況只會越來越多,因為現實是,人們確實應該擔心病患資料被放進 AI 後,可能在各種地方外洩的安全風險。所以,我認為我們正在走出醫療體系中 AI 的「蠻荒西部」階段。我們很自豪在本季宣布 NYP 成為新的 AI 標誌客戶(AI logo)。我們也很自豪宣布 UCSD(同樣是前 20 大醫院)成為新的標誌客戶。但我確實認為你說得對。
I think we are entering this new phase here where hospitals, I think, will rightfully start to say, Okay, what kind of data might we be leaking, and what sites, frankly, do we need to block? They have done that for years and years. It is not a new thing for them. I think they have just been catching up on how much that AI leakage might be happening.
我認為我們正在進入一個新的階段:醫院將會(我認為也理所當然地)開始說,好吧,我們可能正在外洩哪些資料?坦白說,我們需要封鎖哪些網站?他們多年來一直都在做這件事。這對他們來說不是新鮮事。我認為他們只是正在追上:AI 外洩可能發生的程度其實有多大。
Ryan Daniels - Analyst
Ryan Daniels - Analyst
Yeah. Okay. Super insightful. Thank you.
是的。好。非常有洞見。謝謝你。
Operator
Operator
Elizabeth Anderson with Evercore ISI.
Evercore ISI 的 Elizabeth Anderson。
Elizabeth Anderson - Analyst
Elizabeth Anderson - Analyst
Hi, guys. Good afternoon, and thanks so much for the question. Obviously, you talked about the 16 of the top 20 customers, or pharma customers, in terms of three of the pipeline. Can you talk to us about the smaller accounts? Are they also kind of in the same Are they a little bit more reticent, or they're just smaller? And how do we think about the typical ramp of some of these buying? Are they kind of trying it out first and then with future expansion plans in 2027, if that goes well, are they jumping right in? Just a little bit more color on how you see those two segments progressing over the next few quarters to year would be very helpful.
嗨,各位。下午好,也非常感謝讓我提問。很明顯,你們談到在管線的三個項目方面,前 20 大客戶中的 16 家(或製藥客戶)。能否談談較小的客戶?他們是否也有點類似——他們是不是更保守一些,還是只是規模較小?另外,我們該如何看待其中一些採購的典型導入爬坡(ramp)?他們是先試用,然後如果進展順利,於 2027 年再有後續擴張計畫,還是他們會直接大舉導入?如果能多提供一些你們如何看待這兩個客群在未來幾季到一年內的進展,會非常有幫助。
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Great. Liz, this is Jeff. I'll take a first crack and hand to Matt here. Short answer is, we know that the medical-legal review processes of the top 20 pharma are intensive, and we wanted to start there. So we started at the top, if you will, at the most difficult place. And that's been going well. It does take time. Obviously, we have to go through and understand suppression keywords and keywords and where things appear, and there's a lot of testing and all that, but it's all part of the process. And again, we proudly work with, this will be 19 of the top 20 pharma with the three we have in contracting.
很好。Liz,我是 Jeff。我先簡單回答,然後再交給 Matt。簡短的答案是:我們知道前 20 大製藥公司的醫療—法務審查流程非常嚴格,我們希望先從那裡開始。所以如果你願意這麼說,我們是從最上面、也就是最困難的地方開始。而且目前進展良好。這確實需要時間。顯然,我們必須逐一了解需要抑制的關鍵字、關鍵字以及它們出現的位置,還有大量測試等等,但這些都是流程的一部分。再說一次,我們很自豪能與前 20 大製藥公司中的 19 家合作,另外還有 3 家正在簽約流程中。
In terms of smaller accounts, actually things move faster there, but generally speaking, we haven't focused as much on selling to that audience because we think they're going to be the perfect clients for our new auction or biddable tool, and that will be a more efficient go-to-market motion for those smaller accounts. We've started with our more strategic, bigger accounts, which is what we typically do. Again, our best new products go to our best or biggest clients first. But Matt.
至於較小的客戶,其實那邊的進展更快;但整體而言,我們目前沒有把重心放在對那個族群銷售,因為我們認為他們會非常適合我們新的拍賣或可出價(biddable)工具,而那將會是更有效率的市場推進方式來服務這些較小客戶。我們先從更具策略性、規模更大的客戶開始,這也是我們一貫的做法。同樣地,我們最好的新產品通常會先提供給我們最好的或最大的客戶。但 Matt 你來補充。
Matthew Sonefeldt - Chief Financial Officer
Matthew Sonefeldt - Chief Financial Officer
Yeah, I actually don't know if I have that much more to add. I think probably one of the things that signals well is one of the data points from the prepared remarks, which is that based on customer demand, we've made available kind of more than double what we started with in terms of available conditions. That really just speaks to, I think, in a broad set of places that pharma customers are interested in, conditions, drug areas, different types of treatments, you'll see that there's just a lot of interest here. Jeff's point, AI Search is going to become a lot more accessible as we move into FY 2028. So we're excited, we're encouraged. I think the demand is there as we just continue to ramp it up.
是的,我其實不確定我還能補充多少。我想其中一個很正面的訊號,可能是我們在事先準備的講稿裡提到的一個數據點:基於客戶需求,我們已經把可用的適應症(conditions)數量,從一開始的規模擴大到超過兩倍。我認為這真正反映的是,在很廣泛的領域裡,製藥客戶對於各種適應症、藥物領域、不同類型的治療都很有興趣;你會看到這裡的興趣非常高。呼應 Jeff 的觀點,隨著我們進入 2028 會計年度(FY 2028),AI Search 將會變得更容易取得。所以我們很興奮,也很受鼓舞。我認為需求就在那裡,而我們只要持續把規模拉升即可。
Elizabeth Anderson - Analyst
Elizabeth Anderson - Analyst
Yep, that makes a ton of sense. Thanks for all the additional color.
是的,這非常合理。謝謝你補充這麼多細節。
Operator
Operator
Ryan MacDonald with Needham & Company.
Needham & Company 的 Ryan MacDonald。
Ryan MacDonald - Analyst
Ryan MacDonald - Analyst
Hi, thanks for taking my questions. Congrats on the quarter. Jeff, as we think about the example you provided with NewYork-Presbyterian now providing access to the AI solution directly through the EHR, once that occurs within your health system client, what impact do you see or what kind of uplift do you see on usage? Then how important has that sort of uplift or that EHR integration been as you have been going to market with the AI Search product?
嗨,謝謝讓我提問。恭喜這一季的表現。Jeff,當我們思考你提到的例子:NewYork-Presbyterian 現在透過 EHR 直接提供 AI 解決方案的存取;一旦在你們的醫療體系客戶內部發生這件事,你們看到的影響是什麼,或使用量會有什麼樣的提升?另外,在你們推動 AI Search 產品的市場拓展過程中,這種提升或 EHR 整合的重要性有多高?
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Great, Ryan. Yeah, thanks. I will say that with our Patient Context doctors or clients, we have seen roughly a doubling in the amount of usage. Even though they are able to type less themselves because they have more Patient Context coming in, there is a big time savings there. Again, I think that is really the future is, your doctor will be sitting there with you in a visit and the AI will be there with him or her, and it will have, again, your history there so that nothing gets missed. That is really a very exciting future.
很好,Ryan。是的,謝謝。我想說的是,對於使用我們 Patient Context 的醫師或客戶,我們看到使用量大約翻倍。即使他們因為有更多 Patient Context 匯入而能少打一些字,仍然能節省大量時間。再一次,我認為那真的是未來:你的醫師在看診時會坐在你面前,而 AI 會在他或她身旁;而且它會有你的病史在那裡,確保不會遺漏任何事情。那真的是一個非常令人興奮的未來。
With regard to just turning on within an EHR, we have done that in lots of places. I got to be honest, the truth is, just putting a button inside an EHR does not in and of itself get immediate usage. You actually have to do a bit of training and webinars.
至於只是把功能在 EHR 裡打開,我們在很多地方都做過。我必須坦白說,事實是:僅僅在 EHR 裡放一個按鈕,本身並不會立刻帶來使用量。你其實還需要做一些訓練與線上研討會(webinars)。
Maybe this is a sad statement on electronic health records, but a lot of doctors are trained not to click a button if they have not been trained on it. There is just a lot of that sort of hectic behavior around trying out new features or new things inside some of these systems, which have lots of cul-de-sacs and strange behaviors. So, we are good at that. Again, we have been working with them for years, usually as a partner on telehealth and scheduling, and it has actually been fun for our team to have our monthly Zoom call be about a whole new series of features and products. I think we have got many months of good Zoom calls there with our clients to help them see all the things they can do with it.
也許這對電子病歷來說是個有點令人沮喪的說法,但很多醫師被訓練成:如果沒有受過訓練,就不要去點一個按鈕。在這些系統裡嘗試新功能或新事物時,確實存在很多那種忙亂、謹慎的行為;而且這些系統裡有很多死胡同(cul-de-sacs)和奇怪的行為。所以,我們很擅長處理這些。再說一次,我們多年來一直與他們合作,通常是作為遠距醫療與排程方面的合作夥伴;而對我們團隊來說也很有趣,因為我們每月的 Zoom 會議現在是在討論一整套全新的功能與產品。我想我們接下來會有很多個月、與客戶進行很棒的 Zoom 會議,幫助他們看到用它能做到的所有事情。
But short answer is, Patient Context does lead to an immediate lift, but just being inside an EHR, less than you might think.
但簡短的答案是:Patient Context 的確會帶來立即的提升;但僅僅是放在 EHR 裡面,提升幅度比你想像的要小。
Ryan MacDonald - Analyst
Ryan MacDonald - Analyst
That's helpful, color. I appreciate that. Maybe just as a follow-up, as you think about sort of expanding that top-down penetration within the health systems, how valuable do you think the UpToDate partnership can be? Is there any sort of go-to-market sort of relationship there where they can help bring you into, obviously, that very large customer base that they have? Thanks.
這些補充很有幫助。我很感謝。也許再追問一下:當你們思考在醫療體系內自上而下擴大滲透時,你認為與 UpToDate 的合作會有多大價值?是否存在某種市場推進(go-to-market)的合作關係,他們可以協助把你們帶進去——很明顯,他們擁有非常龐大的客戶基礎?謝謝。
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Thanks, Ryan. You're absolutely right. UpToDate is virtually everywhere in the U.S. health system. As I said, our teams have been getting along great. We think that, again, they're just a very high integrity, real boon for the overall health system. So, we're proud to work with them, and we hope and expect to keep expanding our relationships. I don't have anything to announce today on go-to-market with them, but that's some of the things that have been discussed. Let's just say that I think it's a beginning of what we think will be a very strategic, it's a long-term partnership, multi-year. We're excited to keep growing with them.
謝謝你,Ryan。你說得完全正確。UpToDate 幾乎在美國的醫療體系無所不在。如我所說,我們的團隊合作得非常愉快。我們認為,再次強調,他們是一個高度正直、對整體醫療體系非常有助益的夥伴。所以,我們很自豪能與他們合作,也希望並預期能持續擴大彼此的合作關係。今天我沒有任何關於與他們共同市場推進的事項可以宣布,但這確實是我們討論過的一些方向。可以這麼說:我認為這是我們所認定的一個非常具策略性的開端——這是一個長期、多年的合作夥伴關係。我們很期待能與他們一起持續成長。
Ryan MacDonald - Analyst
Ryan MacDonald - Analyst
Awesome. Thanks.
太棒了。謝謝。
Operator
Operator
Scott Schoenhaus with KeyBanc.
KeyBanc 的 Scott Schoenhaus。
Scott Schoenhaus - Equity Analyst
Scott Schoenhaus - Equity Analyst
Hey, guys. Thanks for taking my questions. I just wanted to follow up on Elizabeth Anderson's question. Just wanted to make sure I understood. How long does a typical medical-legal review process take, and how should we think about that ramp in AI Search revenues after you clear that process? Is it very back half weighted in calendar 2027?
嗨,各位。謝謝讓我提問。我只是想跟進 Elizabeth Anderson 的問題。想確認我理解得沒錯。一般的醫療-法務審查(MLR)流程通常需要多久?在你們通過該流程之後,我們應該如何看待 AI Search 營收的爬坡?是否在 2027 年曆年下半年占比會很高?
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
This is Jeff. I'll chime in first. I mean, for new products, MLR review can be months and months. We learned this, candidly, the hard way back with our vertical video product, as you may recall, a few years ago. We had a lot of signed contracts, but we didn't have the revenue coming in for a many month gap because video, honestly, is difficult for lawyers to review well, and there's lots of tools and processes that need to be put in place to be able to comment on frame 68 or 25 seconds in. I think we're being appropriately cautious here in our timeframes, and we're assuming that it will also take many months to get live with these contracts. That does lead to, again, I think, again, a cautiously optimistic approach to the rest of this fiscal year.
我是 Jeff。我先補充一下。我的意思是,對於新產品,MLR 審查可能會持續好幾個月、好幾個月。坦白說,我們幾年前在垂直影片產品上吃過苦頭,你們可能還記得。我們簽了很多合約,但營收在好幾個月的空窗期都沒有進來,因為老實說,影片很難讓律師有效審查,而且需要建立很多工具與流程,才能針對第 68 幀或第 25 秒處提出意見。我認為我們在時程上採取了適度保守的態度,並假設要讓這些合約上線也會需要好幾個月。因此,這也導致——我想——我們對本財年剩餘期間採取審慎樂觀的看法。
Matthew Sonefeldt - Chief Financial Officer
Matthew Sonefeldt - Chief Financial Officer
I'll add a couple of points. I think one is that I think you see that assumption on that gradual ramp, especially kind of from a calendar-year 2027 standpoint in our guidance, right? Our growth rate in Q4 is very similar to our growth rate in Q3, and part of that is because we know that, especially for customers that are buying AI Search for the first time, there will be that ramp up that Jeff described in terms of the MLR process. I would say, in terms of some of our early upfront activity, a lot of the AI Search contracts kind of assume that too, right? It will be a ramp up throughout the next calendar year. That's a dynamic that we're seeing as well.
我再補充幾點。我想第一點是,你們在我們的指引中可以看到對於逐步爬坡的假設,特別是從 2027 年曆年的角度來看,對吧?我們第 4 季的成長率與第 3 季非常接近,其中一部分原因是我們知道,特別是對於第一次購買 AI Search 的客戶,會有 Jeff 所描述的、與 MLR 流程相關的爬坡期。我會說,就我們一些早期的前期活動而言,很多 AI Search 合約其實也把這點納入假設,對吧?它會在下一個曆年逐步爬坡。這也是我們正在看到的一個動態。
I don't think any of that is surprising based on what Jeff described about some of our past product cycles, but that's kind of what the assumptions are that we're making for our business.
基於 Jeff 對我們過去一些產品週期的描述,我不認為這有什麼令人意外,但這就是我們對業務所做的假設。
Scott Schoenhaus - Equity Analyst
Scott Schoenhaus - Equity Analyst
Perfect. Thanks, Matt. Just as a follow-up, so that 6% growth rate for 3Q and then for 4Q, which we start into the next calendar year, typically people read that as a reflection of your view of what maybe the market can grow at or what you can grow at. How should we view that in context of what you're viewing the market growth at as you've outlined 6% growth into the calendar new year? Thanks.
很好。謝謝,Matt。再追問一下,所以第 3 季與第 4 季的 6% 成長率——而第 4 季會進入下一個曆年——一般大家會把這解讀為你們對市場可能成長多少、或你們自身能成長多少的看法。在你們提出進入新曆年仍為 6% 成長的背景下,我們應該如何把它放在你們對市場成長的判斷脈絡中來看?謝謝。
Matthew Sonefeldt - Chief Financial Officer
Matthew Sonefeldt - Chief Financial Officer
Yeah. I think it reflects the beginnings of re-acceleration in our business, right? I provided the comment that our second half, our fiscal second- half outlook has slight acceleration versus our first half. I think that's where you see the beginnings of optimism for us as we look into next year. At the same time, it's early. We're not through our upfront cycle yet, so I think we want to be thoughtful, especially as we think about kind of fiscal Q4 and calendar Q1, see how the upfront lands. Also know that some of the AI Search demand in particular will ramp throughout the year, but I think we're pretty encouraged and optimistic as we sit here today in November for future growth.
是的。我認為這反映了我們業務開始重新加速的跡象,對吧?我提到過,我們下半年——我們財年的下半年展望——相較上半年有些微加速。我想這就是你們看到我們在展望明年時開始出現樂觀情緒的地方。同時,現在還早。我們的前期(upfront)週期還沒結束,所以我認為我們希望審慎一些,特別是在思考財年第 4 季與曆年第 1 季時,先看看 upfront 的結果如何。另外也要知道,尤其是 AI Search 的部分需求會在全年逐步爬坡,但以今天 11 月我們坐在這裡的角度來看,我們對未來成長相當受到鼓舞,也抱持樂觀。
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Scott, I'll just add on the market itself, I think there's some cautious optimism that hopefully next year is better than this year. This year was a perfect storm of a lot of different things not going the market's way. So, I think there's some reasons to be a little more optimistic for next year.
Scott,我再補充一下市場本身。我認為有一些審慎的樂觀,期待明年能比今年好。今年是多種因素同時不利於市場的「完美風暴」。所以,我覺得有一些理由可以對明年稍微更樂觀一點。
Scott Schoenhaus - Equity Analyst
Scott Schoenhaus - Equity Analyst
Thanks, guys.
謝謝,各位。
Operator
Operator
Richard Close with Canaccord Genuity.
Canaccord Genuity 的 Richard Close。
Richard Close - Analyst
Richard Close - Analyst
Yeah. Thanks. Congratulations on the report and the AI progress. Jeff or Matt, just given the comments that AI may be additive and a different buyer, I am curious, do you have separate sales force going after this, or is it the same account teams as the other products? Then with respect to the upfront contracts that you are working on now, is AI bundled in, or is that completely separate since it is a different budget possibly?
是的,謝謝。恭喜這次的報告以及 AI 的進展。Jeff 或 Matt,考量你們提到 AI 可能是增量、而且買方也不同,我很好奇:你們是否有獨立的銷售團隊在推這個,還是與其他產品使用相同的客戶團隊?另外,關於你們目前正在洽談的 upfront 合約,AI 是被打包在一起,還是因為可能屬於不同預算而完全分開?
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Hey, Richard. This is Jeff. Right now, we have an overlay, we call it, but basically a team approach, where we have some new experts we have in the AI Search who join our sales team in meeting with some of these search budget holders. Right now, the contracting, we typically have these master service agreements, and then we have these statements of work, they are called. Sometimes they are together on the same statement of work. Usually, I think it is a separate statement of work. But again, this is the advantage of being a reference client, someone who is already vertically working with all of the top 20 pharma. It has been relatively low overhead for us to add on this Search AI business to existing clients.
嗨,Richard。我是 Jeff。現在我們有所謂的 overlay——基本上是一種團隊式的做法——我們有一些在 AI Search 方面的新專家,會加入我們的銷售團隊,一起去拜訪這些搜尋預算的持有人。
Richard Close - Analyst
Richard Close - Analyst
Okay, thank you.
好的,謝謝。
Operator
Operator
Jessica Tassan with Piper Sandler.
Piper Sandler 的 Jessica Tassan。
Jessica Tassan - Analyst
Jessica Tassan - Analyst
Hi, guys. Thank you very much for the question, and congrats on NewYork-Presbyterian, the 25+ new AI hospital wins. As you guys have started to deploy AI Search, including Patient Context in these enterprise contracts, and commercialize the AI Search offering via pharma bookings, can you help us understand how you're monetizing this product? Basically, what the eight-digit bookings consist of? Are those enterprise subscriptions or pharma bookings, or both? What I'm trying to get at is just in these enterprise contracts, is AI Search exclusively monetized via subscription revenue? So ostensibly for those 190 clients, it might hit at day one. And then is pharma revenue kind of exclusively generated from independent physicians or physician practices using Doximity Ask? Any color there on just how exactly these AI products are being monetized would be super helpful.
嗨,各位。非常感謝讓我提問,也恭喜你們拿下 NewYork-Presbyterian,以及新增 25+ 家 AI 醫院客戶。隨著你們開始在這些企業合約中部署 AI Search(包含 Patient Context),並透過藥廠的預訂(bookings)將 AI Search 產品商業化,你們能否協助我們理解你們如何將這個產品變現?基本上,所謂的八位數預訂金額是由哪些部分構成?那是企業訂閱(enterprise subscriptions)還是藥廠預訂,或兩者皆有?我想釐清的是,在這些企業合約中,AI Search 是否完全透過訂閱收入來變現?因此對那 190 家客戶而言,可能在第一天就會反映?然後藥廠收入是否主要是由獨立醫師或診所使用 Doximity Ask 所產生?如果能就這些 AI 產品究竟如何變現提供一些說明,會非常有幫助。
Matthew Sonefeldt - Chief Financial Officer
Matthew Sonefeldt - Chief Financial Officer
Hey, Jess. This is Matt. Thank you for the question. It's a good one. I would say the primary way we're monetizing, and when we talk about eight-figure bookings, it's primarily with our pharma customers and selling AI Search as an advertising product. We do sell AI as a separate enterprise agreement to health systems customers. We charge a nominal amount as part of our broader workflow suite. So, I think as we think about this going forward, we see the primary monetization engine being on the pharma side of our business, specifically through the ad products that we sell.
嗨,Jess。我是 Matt。謝謝你的問題。這是個好問題。我會說,我們主要的變現方式——以及當我們談到八位數的預訂(bookings)時——主要來自我們的藥廠客戶,並將 AI Search 作為一項廣告產品來銷售。我們也會以獨立的企業協議把 AI 賣給醫療體系客戶。作為我們更廣泛的工作流程套件的一部分,我們收取名目上的費用。因此,展望未來,我們認為主要的變現引擎會在我們業務的藥廠端,特別是透過我們所銷售的廣告產品。
Jessica Tassan - Analyst
Jessica Tassan - Analyst
Okay, that's great. That's extremely helpful. And then just any early thoughts on ROI for the pharma educational content displayed in AI Search relative to Doximity's core business? I think, Matt, you mentioned most of the early upfront bookings are core Doximity, so does that imply kind of parity ROI? Just interested in any early thoughts on ROI for the educational content in AI Search. Thanks again, guys.
好的,那太棒了。這非常有幫助。接著想請教一下,關於在 AI Search 中展示的藥廠教育內容,其 ROI 相較於 Doximity 核心業務,有沒有任何初步看法?我想 Matt,你提到多數早期的預先預訂(bookings)都來自 Doximity 核心業務,所以這是否意味著 ROI 大致持平?只是想了解一下,對 AI Search 中教育內容 ROI 的任何早期想法。再次謝謝各位。
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Hey, Jess. I think the answer is it is just too early. A lot of these programs just launched in the last few months. That being said, this is the most contextually relevant product we have. I think the working thesis is, give us a few more months, we will have more kind of results in. This should be just as, I would say, ROI strong as the other products, if not better. The nice thing is it is also making all of our product portfolio better. There is AI signal now in other products. When you buy AI Search, you are not just buying media, you are buying insights, you are buying retargeting to other parts of the platform. Everything gets better, everything gets, I think, better education at the right time to the right docs.
嗨,Jess。我想答案是現在還太早。這些方案很多都是在過去幾個月才剛上線。不過話說回來,這是我們目前最具情境相關性的產品。我想我們的工作假設是,再給我們幾個月,我們就會有更多結果回來。我會說,這應該會跟其他產品一樣,ROI 很強,甚至可能更好。好處是,它也讓我們整個產品組合變得更好。現在其他產品也有 AI 訊號。當你購買 AI Search,你買的不只是媒體,你買的是洞察,你買的是對平台其他部分的再行銷(retargeting)。一切都變得更好,我想也能在對的時間把更好的教育內容提供給對的醫師。
I think the long and short of it is it is a little too early right now, but the thought is it will be just as good, if not better.
我想簡而言之,現在還有點太早,但我們的想法是它會一樣好,甚至更好。
Operator
Operator
Alexei Gogolev with JPMorgan.
JPMorgan 的 Alexei Gogolev。
Destiny Jackson - Analyst
Destiny Jackson - Analyst
Hi, this is Destiny Jackson on for Alexei Gogolev. I wanted to touch on NRR. I saw that it moved down for overall to 103% and to 106% for top 20. Can you touch on what is driving that trend down, and what are the levers to re-accelerate expansion?
嗨,我是代替 Alexei Gogolev 的 Destiny Jackson。我想談一下 NRR。我看到整體降到 103%,前 20 大客戶降到 106%。你們能談談是什麼因素驅動這個趨勢下滑,以及有哪些槓桿可以讓擴張再加速嗎?
Matthew Sonefeldt - Chief Financial Officer
Matthew Sonefeldt - Chief Financial Officer
Hi, Destiny. Thanks for the question. I would say those metrics tend to follow our revenue growth, and I think we see that as being at a trough level. Like we said, we're expecting the beginnings of re-acceleration in the second half. Usually, those metrics follow the rate of revenue growth. Also, I would say, as we move forward, and something I kind of am thinking about as a newer person in my seat, I think these metrics may not be the right set of metrics to measure our growth going forward. I'll take the customer count one as an example. It's very focused on our largest customers that we've landed and had in place for a long time. It misses our small and medium growth segment, which has been one of the faster-growing segments for several quarters now within our pharma business.
嗨,Destiny。謝謝你的問題。我會說,這些指標通常會跟著我們的營收成長走,而我認為我們目前正處在谷底水準。如同我們所說,我們預期下半年會開始出現再加速的跡象。通常這些指標會跟著營收成長率走。另外我也想說,隨著我們往前走,作為剛坐上這個位置不久的人,我在想這些指標未必是未來衡量我們成長的正確指標組合。我以客戶數這個為例。它非常聚焦在我們已經拿下、且合作很久的最大客戶。它忽略了我們的小型與中型成長客群,而這一塊在我們藥廠業務中,已經連續好幾季是成長較快的區隔之一。
I think we'll see and evolve the right metrics for our next chapter of growth, but it's not something I'm particularly worried about as we consider the opportunities that are sitting in front of us over the next several quarters.
我想我們會看到並逐步演進出適合我們下一個成長篇章的正確指標,但就未來幾季擺在我們面前的機會而言,這不是我特別擔心的事情。
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Destiny, I'd just add on the re-acceleration point. I think there's three things you can look at. One of them is just AI Search, new incremental. We're getting deeper, better breadth at all of our customers, even the existing ones in particular. The core, the other products have higher value because of the search signal. There's more excitement around just the whole portfolio than we've seen in a while. My earlier comment, cautious optimism, the market itself will be a little bit better, at least a little bit better next year than this year. I think all three of those could contribute to improving NRR as we go forward.
Destiny,我再補充一下關於再加速的部分。我認為你可以看三件事。其中之一就是 AI Search,新的增量。我們在所有客戶(尤其是既有客戶)那裡做得更深、覆蓋更廣、效果更好。核心的其他產品因為搜尋訊號而更有價值。整個產品組合的熱度,比我們一段時間以來看到的都更高。我先前提到的「審慎樂觀」:市場本身明年至少會比今年好一些。我認為這三點都可能有助於我們往前提升 NRR。
Destiny Jackson - Analyst
Destiny Jackson - Analyst
Thank you. As a follow-up, the customer count for the customers over $500,000 came down for Q2. Can you touch on what drove that deceleration?
謝謝。追問一下,Q2 超過 50 萬美元的客戶數下降了。你們能談談是什麼原因導致這個放緩嗎?
Matthew Sonefeldt - Chief Financial Officer
Matthew Sonefeldt - Chief Financial Officer
And Destiny, I am going to have you repeat the question again. It just sounded a little garbled on our end.
Destiny,我要請你再重複一次問題。我們這邊聽起來有點斷斷續續。
Destiny Jackson - Analyst
Destiny Jackson - Analyst
Sorry. It was on the customer count for 500,000 customers came down this quarter, so just wanted any color there.
抱歉。是關於 50 萬美元以上客戶的客戶數,這一季下降了,所以想請你們提供一些說明。
Matthew Sonefeldt - Chief Financial Officer
Matthew Sonefeldt - Chief Financial Officer
Oh, right. So Q2 is actually usually one of the weaker quarters for that metric, just from an expand standpoint. We just see less kind of incremental upsell activity. That is basically what I would point to. If you look at past quarters and past Q2s in past years, you see a kind of similar pattern of relative seasonal weakness. That is the primary explanation for that.
喔,了解。所以 Q2 通常在那個指標上本來就是比較弱的季度,主要是從擴張的角度來看。我們看到的增量加購/向上銷售(upsell)活動會比較少。基本上我會指向這一點。如果你看過去幾季、以及往年過去的 Q2,你會看到類似的相對季節性偏弱的型態。這是主要原因。
Destiny Jackson - Analyst
Destiny Jackson - Analyst
Thank you.
謝謝。
Operator
Operator
Allen Lutz with Bank of America.
美國銀行(Bank of America)的 Allen Lutz。
Allen Lutz - Analyst
Allen Lutz - Analyst
Good afternoon, and thanks for taking the questions. First, Jeff, thanks for the shout-out on the survey. Really appreciate that. Can you talk a little bit about the evolution of the competitive landscape here in AI Search? You're looking at really two very different markets in your traditional pharma customer and then the health system customer. Would love to get a sense of how the competitive landscape in each is evolving over time. Thank you.
下午好,謝謝讓我提問。首先,Jeff,謝謝你在調查上特別提到我。真的很感謝。你能談談 AI Search 這裡競爭格局的演變嗎?你們面對的是兩個非常不同的市場:傳統的藥廠客戶,以及醫療體系(health system)客戶。很想了解這兩個市場各自的競爭格局隨時間如何演變。謝謝。
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Thanks, Allen, and I appreciate you listening to the shout-out. I have to say, I've reluctantly come to like your survey, because it is 35 pharmaceutical marketers, which is good coverage, given the top 20 is most of the market. And you do a good job of adding in all the various companies or partners that they work with. Your chart there pointed it out, I think, pretty clearly. We're at the highest level there of interest in incremental dollars we've ever had. Paid search or Google is at the lowest level it's ever been, and some of the new search players there have also dipped, as I think, again, there are ups and downs in the market, and some folks are pleased with their partnerships and some are not.
謝謝,Allen,也謝謝你有聽到我提到你。我得說,我是有點勉強才開始喜歡你的調查,因為它涵蓋了 35 位藥品行銷人員;考量前 20 大幾乎就是市場的大部分,這樣的覆蓋率很不錯。而且你也很擅長把他們合作的各種公司或夥伴都納入。我想你那張圖表把這點講得很清楚。我們在「對新增預算(incremental dollars)的興趣」這個層級上,達到我們有史以來最高。付費搜尋或 Google 則處在史上最低水準,而一些新的搜尋玩家也有所下滑;我想同樣地,市場有起有落,有些人對合作夥伴很滿意,有些則不然。
My short answer to your question is that I think you are pointing us to the fact that these really are two different markets. One is search and one is media. The good news is we're really expanding. A year ago, we were a pure media company, and now we are a media and a search company. As Perry pointed out a few moments ago, there's a lot of synergy between the two, because the reality is Google knowing that you search X here means that they're better able to target you on YouTube there. Those two things go together very well, and that's what we see with our business, our telehealth, which again, is at all-time highs, our scheduling, our other workflow tools in addition to AI Search.
我對你問題的簡短回答是:我認為你指出了一個事實,也就是這確實是兩個不同的市場。一個是搜尋,一個是媒體。好消息是我們正在大幅擴張。一年前我們還是一家純媒體公司,而現在我們同時是媒體公司也是搜尋公司。如同 Perry 剛才提到的,兩者之間有很大的綜效,因為現實是:Google 知道你在這裡搜尋 X,就能更好地在那裡的 YouTube 對你做投放。這兩件事非常相輔相成,而我們在業務上也看到同樣情況:我們的遠距醫療(telehealth)(同樣創下歷史新高)、我們的排程(scheduling)、以及除了 AI Search 之外的其他工作流程工具。
Allen Lutz - Analyst
Allen Lutz - Analyst
Appreciate that color. One for Matt. The margins in the quarter were really strong, and you talked a little in the Q&A around some of the operating levers you could see in the business. Would love to get a sense of, are there opportunities to invest where it would be a high ROI investment? How do you think about investing more in things like AI Search versus maintaining these margins north of 50%? Thank you.
感謝這個補充說明。這題給 Matt。本季的利潤率非常強勁,而你在問答環節也稍微談到了一些你在業務中看到的營運槓桿。想請教是否有機會進行一些投資,而且會是高投資報酬率(ROI)的投資?你如何在加大對 AI 搜尋等項目的投資,與維持 50% 以上的利潤率之間做取捨?謝謝。
Matthew Sonefeldt - Chief Financial Officer
Matthew Sonefeldt - Chief Financial Officer
Yeah. I think you see us making that concerted investment in our EBITDA margin for the full year. I think we have what we feel like is the right firepower to be able to make some of these incremental investments. We literally look at things that we can do differently on a week in and week- out basis, especially right now, given it is such a dynamic time. That has led us to, I think, continue to iterate on the infrastructure that we are using, begin to make investments like in the auction biddable product that Jeff was describing earlier, play offense through some of these partnerships. We will continue to do that. I think what you also see is that we have a really great business model as a company. It generates really incredible incremental margins, especially when we outperform from a revenue standpoint.
是的。我想你們看到我們在全年 EBITDA 利潤率方面進行了有計畫的投資。我認為我們具備我們認為足夠的火力,能夠做出其中一些增量投資。我們確實會逐週、週進週出地檢視有哪些事情可以用不同方式來做,尤其是在當下這樣一個非常動態的時期。這也促使我們,我想,是持續迭代我們正在使用的基礎設施,開始進行投資,例如 Jeff 先前描述的拍賣式可競價產品,並透過一些合作夥伴關係來主動出擊。我們會持續這麼做。我想你們也看到的是,我們作為一家公司擁有非常出色的商業模式。它能帶來非常驚人的增量利潤率,特別是在我們營收表現超出預期時。
We have a really great team who excels at executing. I think you saw that this quarter again. I will share the metric I shared earlier in the Q&A, which is this quarter, our cost of revenue, which is highly AI-focused right now, grew at half of the rate of our prompt volume in our AI products, whereas last quarter, those things were one-to-one. So we saw from that measure a 50% efficiency on our incremental spend. That is just a huge, huge kudos and credit to our team who continues to innovate on AI infrastructure. So we will continue to play offense, very much so, but I am also pretty confident in our ability to generate great incremental margins as we are doing it.
我們有一支非常優秀、擅長執行的團隊。我想你們在本季再次看到了這點。我會分享我先前在問答中提到的指標:本季,我們的營收成本(目前高度聚焦於 AI)成長速度只有我們 AI 產品提示量(prompt volume)成長速度的一半;而上一季兩者是 1:1。因此,從這個衡量方式來看,我們在增量支出上達成了 50% 的效率提升。這對我們持續在 AI 基礎設施上創新的團隊而言,是非常非常大的肯定與功勞。所以我們會持續主動出擊,確實如此;但同時,我也相當有信心,在這麼做的同時,我們仍能產生很好的增量利潤率。
Allen Lutz - Analyst
Allen Lutz - Analyst
Great. Thank you.
很好。謝謝。
Operator
Operator
Ryan Halsted with RBC Capital Markets.
RBC Capital Markets 的 Ryan Halsted。
Ryan Halsted - Analyst
Ryan Halsted - Analyst
Thanks for squeezing me in and taking my question. Any perspectives you can offer on just the general health of HCP marketing budgets going into the upfront season? Just seeing a lot of biopharma activity, lots of new drug approvals. Just curious how you're seeing HCP marketing budgets so far.
謝謝讓我插隊提問並回答我的問題。你們能否分享一些看法,關於在前期採購季(upfront season)到來之際,整體 HCP(醫療專業人士)行銷預算的健康狀況如何?我們看到很多生物製藥活動,許多新藥獲批。想請教你們目前對 HCP 行銷預算的觀察是怎樣的。
Matthew Sonefeldt - Chief Financial Officer
Matthew Sonefeldt - Chief Financial Officer
I can take a first crack at it. This is kind of my first go around in this seat here at Doximity and kind of thinking through the upfront. As I go through it and I compare it to a lot of the team's experience last year, I think it feels like a more stable environment. I wouldn't say it's world-beating or having a massive growth uplift. I think there are some dynamics in terms of pharma approval pipelines that are improving. Whereas last year there was a lot of policy uncertainty and friction, I think that is stabilizing, although I wouldn't say it's kind of up and to the right. I think it feels like a more stable, a more comfortable environment to do business in, but not necessarily one that's dramatically re-accelerating from a macro standpoint.
我先嘗試回答一下。這算是我在 Doximity 這個職位上第一次經歷 upfront,也在思考 upfront 的情況。當我走過這個流程,並與團隊去年大量的經驗相比,我覺得環境更穩定一些。我不會說是表現驚人或出現大幅成長的提振。我認為在製藥核准管線方面有一些動態正在改善。相較之下,去年有很多政策不確定性與摩擦,我認為這些正在趨於穩定,雖然我不會說是一路向上。我覺得整體而言,這是一個更穩定、更舒適的商業環境,但從宏觀角度來看,未必是明顯重新加速的環境。
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Yeah, this is Jeff. I'll just add, if you look at the iShares Pharma ETF, it's up about 40% year on year. You think about where we were a year ago compared to today, again, there were a lot of negotiations around price and tariffs, and there was just a lot of things in the mix that I think we look at this year as a more stable environment for us to grow and do our jobs.
是的,我是 Jeff。我再補充一下,如果你看 iShares 製藥 ETF,年對年大約上漲 40%。想想一年前我們所處的位置與今天相比,同樣地,當時有很多關於價格與關稅的談判,還有很多事情混在一起;我認為今年我們把它視為一個更穩定的環境,讓我們能成長並做好我們的工作。
Operator
Operator
There are no further questions at this time. I will now turn the call back to CEO, Jeff Tangney for closing remarks.
目前沒有其他問題。我現在把電話交回給執行長 Jeff Tangney 作結語。
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
I would like to end by thanking the entire Doximity team for their hard work serving more doctors every day than ever before. Thank you, everyone, for joining.
最後,我想感謝整個 Doximity 團隊的辛勤付出,讓我們每天服務的醫師數量都比以往更多。謝謝各位的參與。
Operator
Operator
This concludes today's call. Thank you for attending. You may now disconnect.
今天的電話會議到此結束。感謝各位出席。您現在可以掛線。